Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
Fish and Richardson
Queensland Health

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,855,290

« Back to Dashboard

Summary for Patent: 4,855,290

Title: Derivatives of quinuclidine
Abstract:Quinuclidine derivatives having the general formula (I) ##STR1## and geometrical isomers, enantiomers, diastereoisomers, racemates and/or acid addition salts thereof, wherein Z represents the group >CR.sup.1 R.sup.2 or two hydrogen atoms; and R.sup.1 and R.sup.2, which may be identical or different, are each alkyl, cyclopentyl, cyclohexyl, aryl, or diarylmethylol, or alkyl which is substituted by one or more aryl groups, or one of R.sup.1 and R.sup.2 may be hydrogen.
Inventor(s): Fisher; Abraham (Holon, IL), Karton; Ishai (Ness-Ziona, IL), Heldman; Eliahu (Rehovot, IL), Levy; Aharon (Moshav Beith Hanan, IL), Grunfeld; Yona (Rehovot, IL)
Assignee: State of Israel, represented by Prime Minister's Office, Israel (Ness-Ziona, IL)
Application Number:06/853,404
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,855,290

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel75166May 10, 1985
Israel77568Jan 10, 1986

International Patent Family for Patent: 4,855,290

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0205247► Subscribe
Germany3687288► Subscribe
Denmark196686► Subscribe
Denmark173084► Subscribe
Canada1311479► Subscribe
Australia6485986► Subscribe
Spain554280► Subscribe
Australia599610► Subscribe
Austria83485► Subscribe
Argentina242213► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Queensland Health
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus